Zenyatta Ventures Ltd. Announces Voting Results from 2013 Annual and Special Meeting of Shareholders

Zenyatta Ventures Ltd. (the “Company”) (TSXV: ZEN) is pleased to advise on the results of the voting on the matters submitted to the annual and special meeting (the “Meeting”) of the shareholders (the “Shareholders”) of the Company held on September 10, 2013. Shareholders voted in favour of all items of business at the Meeting, including: (i) the reappointment of McGovern, Hurley, Cunningham, LLP, Chartered Accountants as auditors of the Company; (ii) the election of each director nominee, being Aubrey Eveleigh, Clifford Davis, Brian Davey, Barry Allan and Peter J. Ravenscroft; (iii) the annual approval of the Company’s existing 10% “rolling” stock option plan as mandated by the policies of the TSX Venture Exchange; and (iv) the approval and ratification of amendments to the Company’s By-laws to include advance notice provisions (the “Advance Notice Provisions”) where a Shareholder wishes to make a nomination to the board of directors other than pursuant to: (A) a requisition of a meeting of shareholders made pursuant to the provisions of the Business Corporations Act (Ontario) (the “Act”); or (B) a shareholder proposal made pursuant to the provisions of the Act. The purpose of the Advance Notice Provisions is to provide Shareholders, directors and management of the Company with a clear framework for nominating directors. Among other things, the Advance Notice Provisions fix a deadline by which Shareholders must submit nominations to the Company prior to any annual or special meeting of Shareholders, and sets forth the minimum information that a Shareholder must include in the notice to the Company for the notice to be in proper written form. To find out more on Zenyatta Ventures Ltd., please visit website www.zenyatta.ca or contact the Company at info@zenyatta.ca or Tel. 807-346-1660. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
  • Share

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.

To find out more about Zentek Ltd., please visit our website at www.zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR profile at www.sedar.com.

Forward-Looking Statements

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information:

Tyler Dunn

Director, Marketing & Communications

tdunn@zentek.com

Subscribe for Updates

Interested in recieving press releases directly to your inbox? Subscribe to Zentek's mailing list for all the latest news.